Hepatitis virus and hepatocellular carcinoma: recent advances
C Shen, X Jiang, M Li, Y Luo - Cancers, 2023 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is a global health challenge. Hepatitis
virus infection (including HBV, HCV and HDV) is one of the major risk factors for HCC …
virus infection (including HBV, HCV and HDV) is one of the major risk factors for HCC …
Deregulation of ribosomal proteins in human cancers
W El Khoury, Z Nasr - Bioscience Reports, 2021 - portlandpress.com
The ribosome, the site for protein synthesis, is composed of ribosomal RNAs (rRNAs) and
ribosomal proteins (RPs). The latter have been shown to have many ribosomal and …
ribosomal proteins (RPs). The latter have been shown to have many ribosomal and …
Enzyme-responsive microneedle patch for bacterial infection and accelerated healing of diabetic wounds
S Wu, B Qin, X Tang, T Cui, S Yin, H Dong, Y Liu… - Chemical Engineering …, 2023 - Elsevier
Chronic diabetic wounds are caused by an array of pathologies. Pathogenic bacteria such
as S. aureus can easily invade hosts with deficient immunity. In this study, we developed a …
as S. aureus can easily invade hosts with deficient immunity. In this study, we developed a …
[HTML][HTML] GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
Q Zhou, Y Yin, M Yu, D Gao, J Sun, Z Yang, J Weng… - Redox biology, 2022 - Elsevier
Guanosine triphosphate binding protein 4 (GTPBP4) is a key regulator of cell cycle
progression and MAPK activation. However, how its biological properties intersect with …
progression and MAPK activation. However, how its biological properties intersect with …
Structural, molecular, and functional insights into Schlafen proteins
Schlafen (SLFN) genes belong to a vertebrate gene family encoding proteins with high
sequence homology. However, each SLFN is functionally divergent and differentially …
sequence homology. However, each SLFN is functionally divergent and differentially …
Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma
C Zhou, J Weng, C Liu, S Liu, Z Hu, X Xie, D Gao… - Gastroenterology, 2023 - Elsevier
Background & Aims The therapeutic effect of immune checkpoint inhibitors (ICIs) is poor in
hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) …
hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) …
Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing
S Zhao, W Ji, Y Shen, Y Fan, H Huang, J Huang, G Lai… - BMC cancer, 2022 - Springer
Background This study aimed to use single-cell RNA-seq (scRNA-seq) to discover marker
genes in endothelial cells (ECs) and construct a prognostic model for glioblastoma …
genes in endothelial cells (ECs) and construct a prognostic model for glioblastoma …
LncRNA MEG3 inhibits tumor progression by modulating macrophage phenotypic polarization via miR-145-5p/DAB2 Axis in hepatocellular carcinoma
Q Wei, G Liu, Z Huang, Y Huang, L Huang… - Journal of …, 2023 - Taylor & Francis
Background Hepatocellular carcinoma (HCC) is the predominant histological type of primary
liver cancer, which ranks sixth among the most common human tumors. Tumor-associated …
liver cancer, which ranks sixth among the most common human tumors. Tumor-associated …
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
C Winkler, J Armenia, GN Jones, L Tobalina… - British Journal of …, 2021 - nature.com
Abstract Background Schlafen 11 (SLFN11) has been linked with response to DNA-
damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects …
damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects …
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
Schlafen-11 (SLFN11) inactivation in∼ 50% of cancer cells confers broad chemoresistance.
To identify therapeutic targets and underlying molecular mechanisms for overcoming …
To identify therapeutic targets and underlying molecular mechanisms for overcoming …